Vivus Muse impotency campaign to raise public awareness following January launch.
Executive Summary
VIVUS MUSE IMPOTENCE PUBLIC AWARENESS CAMPAIGN WILL ACCOMPANY LAUNCH of product in January. The campaign will be directed at physicians and consumers. The company's marketing campaign will also focus on the 8,000 urologists in the U.S., Vivus said. Muse (alprostadil) urethral suppository was approved on Nov. 19 for treatment of erectile dysfunction following an eight-month review; NDA 20-700 for Muse was submitted on March 27.